REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Clinical trials for REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug combo shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and vorinostat (a drug that blocks enzymes cancer cells need to grow)—in 52 adults with certain types of lymphoma that had returned or stopped resp…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Double-targeted cell therapy takes on hard-to-treat blood cancers
Disease control OngoingThis early-phase trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to recogniz…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New hope for hard-to-treat lymphoma: targeted drug combo shows promise
Disease control OngoingThis study tests a new combination of drugs (polatuzumab vedotin plus standard chemotherapy and immunotherapy) as the first treatment after lymphoma returns or doesn't respond. About 41 adults with diffuse large B-cell lymphoma will receive this therapy to see if it can shrink tu…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:38 UTC